A B S T R A C T The physiological basis for the polyuria and polydipsia occurring in some manic-depressive patients treated with lithium salts was studied in vivo and in vitro. Three lithium-treated polyuric patients, in whom other causes of a concentrating defect were excluded, had abnormal urinary concentrating abilities after a standard water depreviation test. Two of these patients failed to respond to exogenous vasopressin (ADH) and one had a subnormal response. The abilities of these patients to excrete solute-free water (CI20) was comparable to normal subjects during steady-state water diuresis, suggesting no gross abnormalities in sodium transport. However, each of these patients demonstrated abnormally low capacities to reabsorb solutefree water (TCHo) under hydropenic conditions after administration of hypertonic saline and vasopressin. These in vivo findings demonstrate at least a nephrogenic basis for the diabetes insipidus syndrome manifested by these three patients.
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The defect in water transport was further characterized in toad urinary bladders in vitro. Short-circuit current (I) and water flow (W) were studied under basal, ADH-stimulated, and cyclic adenosine 3',5'-monophosphate (c-AMP)-stimulated conditions. Increasing mucosal [Li'] progressively inhibited basal I, and both I and W induced by ADH. Significant inhibition of basal and ADH-induced I was observed at mucosal [Lii] < 1.1 mEq/liter, and of ADH-induced W at mucosal [Li'] = 11 mEq/liter. On the other hand, at these lithium concentrations, neither c-AMP-stimulated W nor I was inhibited. Increasing serosal [Li'] produced significant inhibition of basal I only at [Li'] at least 50-fold greater than at the mucosal (urinary) surface.
These in vitro studies confirm that mucosal lithium inhibits the action of ADH, but not c-AMP. Hence, lithium
INTRODUCTION
Lithium carbonate is a new orally active agent currently enjoying widespread use for the treatment of the manic phase of manic-depressive disorders. Listed among the less commonly occurring side effects of the administration of lithium salts are polyuria and polydipsia (1) . Recently, both clinical observations (2, 3) and preliminary data obtained in experimental animals (4, 5) suggest that lithium can produce a reversible nephrogenic diabetes insipidus syndrome. However, the precise pathophysiology of the renal defect remains undefined.
Persistent excretion of large volumes of hypotonic urine, as occurs in some patients treated with lithium carbonate, could be due to (a) psychogenic water drinking, (b) central diabetes insipidus, and (c) nephrogenic diabetes insipidus. These possibilities were evaluated by a standard water-deprivation test, followed by vasopressin administration, with determination of the maximum urinary concentrating ability (Umax).' The ability of the kidney to reabsorb solute-free water (TCH20) was evaluated under hydropenic conditions after the administration of hypertonic saline; this method of estimating TCH20 depends on the permeability of the collecting ducts to water, the capacity of the ascending limb of the loop of Henle to transport sodium, and the extent to which tubular fluid equilibrates with the cortical and medullary interstitium (6) . The ability of the kidney to excrete solute-free water (CI2o) was determined under steadystate water diuresis; this method of estimating CH2o depends on the volume of fluid presented to, and the sodium transport occurring in, the distal nephron (7) .
Since there are many factors which can underlie any abnormalities in human clearance studies, an in vitro preparation was used to evaluate the effects of lithium on ion transport and water flow more precisely. The isolated toad urinary bladder has often been used as a physiological mnodel for the distal portions of the mammalian nephron (8) . In these studies, sodium transport was evaluated by studying short-circuit current, and water flow was studied both volumetrically and gravimetrically. Both basal and ADH-induced transport were investigated in the presence and absence of lithium.
A preliminary report of some of these results has been presented elsewhere (9) .
METHODS

In vivo studies
Studies were performed on three polyuric male subj ects ranging in age from 27 to 53 yr. Each of these patients were hospitalized on the psychiatric ward of the Philadelphia Veterans Administration Hospital with a diagnosis of manic-depressive psychosis. They were all treated with lithium carbonate in divided doses, ranging from 1500 to 2400 mg/day. They were taking unrestricted (approximately 4 g) sodium diets and had normal glomerular filtration rates (90-105 ml/min). Other causes of a concentrating defect, including therapy with other drugs, hypercalcemia, hypokalemia, thyroid disease, and hypertension, were excluded. Since each of the patients complained of polyuria and polydipsia for the first time after the introduction of lithium therapy, this drug was suspected despite serum lithium levels which were consistently within the accepted therapeutic range of 0.5 to 1.5 mEq/liter (1).
After informed written consent was obtained, each patient underwent a series of three studies: (a) determination of maximal urinary concentrating ability (Umax) after water deprivation and exogenously administered vasopressin; (b) determination of the maximal free-water clearance (CH-2o) and formation of a maximally dilute urine (Um.n); and (c) determination of the maximal solute-free water reabsorption (TCH20) during hydropenia and hypertonic saline diuresis. (Five normal men served as controls and were evaluated in a similar manner to the three patients.)
Studies of concentrating ability (Uraz). Under constant observation, the patients were deprived of fluid for a period of 12 hr, or until they had lost 3-4% of body weight (whichever occurred first). Blood and urine samples were obtained for determination of osmolality at the outset of the study, and at 4-hr intervals until the study was terminated. At the end of the water deprivation period, 10 U of aqueous vasopressin (Pitressin; Parke, Davis & Co., Detroit, Mich.; lot #KB121) was administered subcutaneously. Urine specimens were collected for another 1-2 hr, at which time blood was again obtained, and the osmolalities of all specimens were determined.
Studies of diluting ability (Umin) and free-water clearance (CH20). Food was withheld after the midnight before the study, but the patient was allowed water. The patient voided at 8 a.m., and base line studies of blood and urine were obtained; the patient remained in a recumbent position thereafter, except when voiding. Standard priming doses of inulin and p-aminohippurate (PAH) were given intravenously, and a sustaining infusion of physiological saline containing both agents was initiated at a rate of 1.0 ml/min. After a 45-60 min equilibration period, a urine specimen was obtained, and a 20 ml/kg body weight oral water load was administered over a 20-30 min period. Urine volumes were determined every 10-30 min, and an equivalent volume of tap water was replaced orally, with an additional 0.7-1.0 ml/min to replace insensible losses. This procedure continued until steady-state urine flow was achieved. Blood samples were obtained at approximately 30-to 45-min intervals throughout the study.
Studies of solute-free water reabsorption (TCH2o). Measurement of TCHo during hypertonic (3%) saline diuresis was performed as follows. Both food and water were omitted after the midnight before the study, and no oral intake was allowed except for 5-10 ml water taken with a regularly scheduled dose of lithium. The patient voided at 8 a.m. and assumed recumbency for the remainder of the study after base line studies were obtained, as above. Priming and sustaining doses of inulin and PAH were given in an infusion containing vasopressin, and the solution was administered at a rate calculated to deliver 360 mU/hr. After a 40-45 min equilibration period, the patient voided and an intravenous infusion of 3%o saline was begun at a rate of 10-12 ml/min. Urines were collected every 10-30 min, and blood samples were collected every 45-60 min throughout the study.
Specimen analysis. Blood and urine were analyzed for sodium and potassium by flame photometry. Osmolalities were determined with an Advanced Osmometer (Advanced Instruments Inc., Newton Highlands, Mass.; Model 68-3L). Inulin and PAH were measured by methods described previously (7) . Glomerular filtration rates and effective renal plasma flow rates were determined by the clearances of inulin (Cin) and PAH (CPAH), respectively.
Calculations. Osmolar clearance (Co.m), free water clearance (CH20), and tubular reabsorption of solute-free water (TeH2o) were determined from the following formulae: Cosm = UosmV/Posm; CH20 = V-Cosm; TCH20 = Cosm-V; where V= urine flow rate (ml/min), Uosm = urine osmolality, and Posm = plasma osmolality (mOsm/kg).
In vitro studies
Urinary bladders were excised from doubly pithed female toads, Bufo marinus, obtained from the Dominican Republic (National Reagents, Bridgeport, Conn.). The excised hemibladders were placed in continuously aerated NaCl-Ringer's solution at room temperature (22-24°C) A double chamber, similar to those described by Sharp and Leaf (10) and based on the techniques of Ussing and Zerahn (11) , was used to study transepithelial potential difference and short-circuit current. In all chamber experiments, the hemibladders were mounted across the entire chamber, so that half of a single hemibladder isolated its own serosal and mucosal compartments (cross-sectional areas of 2.3 cm2). In this manner, a single hemibladder provides an experimental and a control quarter bladder.
The transepithelial potential difference (V) and the shortcircuit current (I) across each quarter-bladder were measured intermittently by methods described previously (12) , using Keithley 200 B Electrometers and a Weston 622 Microammeter, respectively. In all cases V and I were followed until a stable base line was obtained for at least 20 min before any experimental manipulations. V, I, and water flow were usually determined at intervals of 5 min or less. Bladders with base line V < 5.0 mv or I < 5.0 Aa were discarded in all experiments.
A double chamber with closed mucosal compartments and horizontally mounted pipettes, similar to that described previously (12) , was used for simultaneous measurements of electrical properties 2 and water flow (compartment crosssectional areas of 2.0 cm2). Paired quarter-bladder experiments with either control water flow rate greater than 2.0 itl/min, or whose control quarter bladder failed to respond to vasopressin (at least 6-fold increase in water flow rate) were not used. The mucosal compartments contained the appropriate Ringer's solution diluted in half with distilled water to provide the osmotic gradient. Solutions in each compartment (volume, 5.0 ml) were changed by draining and refilling with the next solution.
Osmotic water flow was measured also in paired hemibladders mounted on glass tubes ("bags") as described by Bentley (13) . The appropriate Ringer's solution was diluted in half with distilled water, and placed inside each hemibladder to bathe the mucosal surface (volume, 5.0 ml); the serosal surface of each hemibladder was bathed in isotonic NaCl-Ringer's solution. Weight loss was measured for at least 30 min before vasopressin was added. Paired hemibladder experiments whose control hemibladder failed to respond to vasopressin (see above) were not used.
After a stable base line was obtained in both chamber 
RESULTS
IN VIVO STUDIES
The data summarizing the responses of the three lithium-treated patients studied to maximal hydropenia and vasopressin administration are presented in Fig. 1 . In 2 The current measurements with an osmotic gradient were only used to document the presence of lithium inhibition and to monitor bladder viability in these water-flow studies. Although the qualitative current results with a gradient were similar to those obtained without a gradient, all of the data in the Results section was obtained without a gradient. (14) , patients and normal subjects formed comparable amounts of free water per 100 ml of glomerular filtrate. In each instance the patients were also able to achieve a normal minimum urine osmolality of < 90 mOsm/kg H20.
The capacity of these patients to reabsorb free water (TCH20) was measured during increasing rates of sodium and water delivery to the distal nephron. In Fig. 3 a. Mucosal lithium. Substitution of lithium for increasing fractions of the mucosal sodium resulted in significant decreases in both electrical potential difference (V) and short-circuit current (I) when the mucosal [Li'] was greater than 1.1 mEq/liter. These electrical responses were usually observed within 10 min, and reached a maximum change within 20 min after the substitution; the responses usually persisted at these new levels for at least 60 min when compared to control quarter-bladders with choline replacing the same fraction of the mucosal sodium. A representative paired quarter-bladder experiment of this kind is shown in Fig. 4 , and the results of similar experiments at different concentrations of mucosal lithium are summarized in Fig. 5 11 .0 mEq/liter substitution of Li+ for Na+ had a significant additional effect on the ADH-induced current response; a typical experiment is shown in Fig. 4 , and the results are summarized in Fig. 6 , right. Nearly total replacement of the mucosal Na' with Li' produced a sim- ilar degree of additional inhibition (solutions as in section la, AI% = -34--9%; n = 6; P < 0.02).
Substitution of Li' for Na' in the serosal medium had no additional inhibitory effect on the ADH-induced current response (i.e., above that which should be accounted for by base line inhibition). For example, at serosal [Li'] = 55.0 mEq/liter, AI% = +22±9% (n =8; NS).
b. Water flow. When studied in paired quarterbladders (volumetric chamber method), substitution of Li+ for Na' in the mucosal medium was without effect on base line water flow in response to a 2: 1 osmotic gradient. (In each case, the experimental quarter-or hemibladder had Li' substituted for Na* before dilution, and the control had Ch+ substituted for the same fraction of the mucosal Na+.)
However, ADH-induced water flow was significantly inhibited when the initial mucosal [Li'] was 11.0 mEq/ liter before dilution. A typical experiment of this type is shown in Fig. 7 , left, and the results are summarized in Fig. 6 , left. Increasing' the initial mucosal [Li'] to 55.0 mEq/liter before dilution was without any further inhibitory effect (AW%= 16±8%; n 12; P > 0.05).
These results were confirmed in paired hemibladder experiments (gravimetric bag ;method). With an initial mucosal [Li'] = 11.0 mEq/liter before dilution, the mean +SEM inhibition of ADH-induced water flow was -46±10% (n=9; P < 0.005). Although this degree of inhibition is much greater than that observed in chamber experiments, the difference may be accounted for by the much larger surface area utilized to observe flow in bag experiments.-However, even with the more sensitive gravimetric method, reduction of the initial mucosal [Li+] to 5.5 mEq/liter before dilution failed to produce significant inhibition of the ADH-induced water flow response (AW% =-33±19%; n = 10; P > 0.1).
3. Effects of lithium on cyclic adenosine 3', 5'-monophosphate (c-AMP) responsiveness a. Short-circuit current. Mucosal Li+ at concentrations of 1.1 mEq/liter and of 11.0 mEq/liter, which produced significant inhibition of base line current at both concentrations, and additional inhibition of ADH-responsiveness at the higher concentration, failed to inhibit the response to c-AMP. These results are summarized in comparison to ADH in Fig. 8 11; NS); these c-AMP observations are in sharp contrast to the lithium inhibition of ADH-induced water flow, described above. DISCUSSION Lithium-induced concentrating defects, although only recently described, are probably not uncommon (5) . To investigate the mechanisms responsible for the lithiuminduced renal concentrating defect, we utilized current models of the urinary concentration and dilution mechanisms (6) . As the glomerular filtrate courses through the ascending limb of the loop of Henle, sodium is transported into the interstitium in excess of water. In the absence of ADH, the hypotonic fluid thus entering the early distal tubule may be further diluted by the reabsorption of sodium chloride at relatively water-impermeable cortical diluting sites, and a dilute urine is excreted. In the presence of ADH, the passive movement of solutefree water from the isotonic tubular fluid in the collecting duct to the hypertonic medulla results in excretion of a concentrated urine. Thus, renal concentrating defects in the presence of circulating ADH mnay be produced by (a) depressions in GFR which limit the delivery of sodium-containing fluid to the loop of Henle and the collecting duct, (b) defective sodium transport in the ascending limb of the loop of Henle, (c) abnormal medullary blood flow which disturbs the osmotic gradient, and (d) depressed responsiveness of the distal tubular epithelium and collecting duct to ADH.
Each of our three patients clearly demonstrated a concentrating defect when challenged with prolonged hydropenia plus vasopressin administration. Of interest is the To differentiate among the possible causes of the renal concentrating defect, the patients were studied under conditions of maximal sustained water diuresis to test their ability to excrete free water and thus estimate distal sodium transport at the diluting sites. Since the ability of our patients to excrete free water compared favorably to a group of normal subjects used as controls, we conclude that sodium transport in the ascending limb of the loop of Henle and the other diluting segments was grossly normal. However, studies during hypertonic saline and vasopressin infusions revealed a decreased TeH2o at low and moderate rates of sodium delivery. These data suggest that the lithium-induced concentrating defect in man is most likely due to impaired water flow across the collecting duct epithelium rather than abnormal sodium pumping by the ascending limb of the loop of Henle. Our studies do not exclude, as additional mechanisms, either the inability to maintain an osmotic gradient in the medulla or abnormal sodium transport by the distal nephron at higher rates of sodium delivery than were achieved in these studies.
Since the diabetes insipidus in these three lithiumtreated patients was confirmed to be nephrogenic, the effects of lithium on salt and water transport by toad urinary bladders were studied to further characterize the mechanism by which lithium impairs the response of the mammalian kidney to ADH. In principle, lithium could affect salt and/or water transport by altering basal transport characteristics, ADH responsiveness, or both; furthermore, the action of lithium may be at the mucosal surface, the serosal surface, or both. The present studies demonstrate that (a) very low concentrations of lithium inhibit basal sodium transport, (b) higher concentrations of lithium inhibit ADH-induced sodium transport and water flow in response to an osmotic gradient, and (c) lithium probably acts at the mucosal surface.
Under basal conditions lithium is both accumulated by toad urinary bladders (15) and transported by both frog (16) and toad urinary bladders, although less well than sodium (15) . It has also been suggested that lithium may compete with sodium for entry at the mucosal membrane in toad bladders (17) . It might be argued that replacement of a fraction of the mucosal sodium with the less well transported lithium would then be expected to produce inhibition of the short-circuit current. Therefore, we compared the effects of lithium substitution (experimental preparations) to those of choline substitution (control preparations) for the same fraction of the sodium present. Since choline is not transported, and since up to 50% replacement of the mucosal sodium with choline has no effect on sodium transport (18) , any transport of lithium would tend to minimize the observed inhibitory effect on short-circuit current. Therefore the observed inhibitory effects of lithium cannot be attributed to a reduction in the concentration of sodium present, and are likely to be underestimated to the extent that lithium is itself transported.
Lithium was found to inhibit basal short-circuit current at concentrations of 0.7 mEq/liter in the mucosal medium. Increasing inhibition was observed at increasing lithium concentrations up to 5.5 Whereas lithium is an effective inhibitor of basal sodium transport at very low concentrations in the mucosal medium, and only at very high concentrations in the serosal medium, it is likely that the inhibitory action takes place at the mucosal surface. Similarly, high serosal lithium concentrations are without effect on the ADH response, whereas lower mucosal concentrations do affect the ADH response. In fact, the serosal effect of high concentrations of lithium may be the result of backdiffusion into the mucosal medium. If applicable to man, these findings suggest that the urinary rather than the blood levels of lithium may be clinically important in the production of nephrogenic diabetes insipidus. However, the clinical study provided no evidence for impaired sodium transport, and there is no evidence for ADH-induced sodium transport in man.
On the other hand, it is clear that ADH-induced water flow does occur in man, as it does in toad urinary bladder. The present studies demonstrate significant lithium inhibition of ADH-induced water flow both in chamber (15-20%) of c-AMP (20, 21) , and since c-AMP mimics the actions of ADH to accelerate both sodium and water transport across toad urinary bladder, the effects of lithium on c-AMP-induced transport were studied. c-AMP-induced transport of either sodium or water was not significantly affected by lithium concentrations which inhibited ADH-induced transport. These data suggest that the effects of lithium on ADH-induced transport are exerted at a site biochemically proximal to the action of c-AMP. Furthermore, lithium is known to inhibit the production of c-AMP by various adenyl cyclase systems in vitro, including brain, thyroid, and kidney (22) (23) (24) . Recently, Forrest, Cohen, Torretti, and Epstein (5) reported that lithium produced nephrogenic diabetes insipidus in rats, and that c-AMP failed to increase Uosm above Posm under these conditions. From these data, the authors suggested that lithium interfered with the action of ADH at a site beyond the production of c-AMP. Although these findings with different doses in a different preparation cannot be entirely reconciled with our results, a significant rise in Uo0m, even if not above Poem, may mean a subnormal but significant increase in water transport was induced by c-AMP. Our findings are also supported by a recent study of rabbit kidney adenyl cyclase, where a direct assay of c-AMP production showed that lithium inhibited ADH interaction with adenyl cyclase (24) . The methods employed in that study effectively exclude the alternative possibility that lithium increases c-AMP destruction (25) . The possibility that lithium also inhibits c-AMP action (5) is not excluded.
In conclusion, our in vivo study has documented impaired ADH-induced water flow across the collecting ducts underlying nephrogenic diabetes insipidus in three patients treated with lithium carbonate for manic-depres- sive disorders. In vitro studies with toad urinary bladders suggest that lithium exerts its action on the renal concentrating mechanism from the urinary surface, and that the mechanism of action is at least in part inhibition of ADH-stimulated production of c-AMP.
